Speaker Profile
Ph.D., RAC, Senior Director and Diagnostics Lead, Oncology Programs, Genomic Science and Technology, Pfizer
Biography
Dr. Perez has over 15 years experience in diagnostic and drug development. He currently oversees companion diagnostic development activities for the oncology portfolio at Pfizer. He previously served as the Director for R&D Diagnostics at Tocagen where he led the preclinical and diagnostic assay development efforts for Toca 511, a gene therapy product for glioblastoma. Prior to Tocagen, Dr. Perez was the Senior Director of Research and Technology at Nodality Inc., a diagnostic company he co-founded. Prior to Nodality, Dr. Perez was the Senior Scientist and Director of the phospho-protein flow cytometry group at the Stanford Proteomics Center in the Stanford Medical Center, overseeing project management for antibody screening procedures, autoimmune clinical studies, and small compound profiling for many major pharmaceutical companies.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: A tremendous amount of work and effort is put into FDA approval of a drug, yet often the necessary accompanying diagnostics are not in place to meet the needs in a timely fashion. Upstream processes, such as tighter collaborations between pharma and diagnostics companies, more robust and earlier assay development, better transition of translational insight into clinical applications, or clinical trial design itself need to be optimized. This session’s dialogue will focus on these aspects and how a critical diagnostics component can be optimally integrated into a commercial strategy to create a more efficient and successful approval and commercialization process.
